Merck stops Vioxx sales worldwide

New clinical trial data showing the arthritis drug Vioxx increases the risk of stroke and heart attack has prompted Merck to voluntarily pull it from the market. "We are taking this action because we believe it serves the best interest of patients," said Raymond Gilmartin, the company's chairman and CEO. Merck sold $2.5 billion worth of Vioxx in 2003.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA